Clinical Trials · NCT07159451
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Enrollment
- 140
- Start date
- Oct 2025
- Locations
- 1 site, France
- Primary endpoint
- To determine if 4 weeks of elacestrant monotherapy determines a non-inferior anti-proliferative effect, measured by Ki67, in comparison to elacestrant with leuprorelin in premenopausal patients with ER-positive/HER2- operable invasive BC.